Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.IsoRay has reported that it has successfully shipped the first set of Cesium-131 brachytherapy seeds to a Canadian customer for the purpose of furthering research and development of Cesium-131 in Canada. Cesium-131 is currently approved by Health Canada for the treatment of low-risk prostate cancers and has been cleared by the FDA for treatment of a wide variety of malignant disease.
Subscribe to our email newsletter
IsoRay Medical, in conjunction with its Canadian distribution partner, Inter V Medical, looks forward to expand the application of Cesium-131 for other cancer treatment areas of the body. IsoRay is seeking additional clinical evidence to allow Health Canada to approve expanded indications for use of Cesium-131 for other malignant disease locations. The goal is to obtain approvals for a wide variety of malignant disease sites (as has already been obtained in the US).
Dwight Babcock, chairman and CEO of IsoRay, said: “We are very excited to take this first step in gathering clinical data to support the expanded use of Cesium-131 in Canada. We have experienced successful treatments of numerous cancers here in the US, such as lung, head and neck, and colon cancers, and look forward to bringing this technology to physicians in Canada to use in treating their patients. We are working closely with our distribution partner Inter V Medical to expedite the penetration of the Canadian market.
“Inter V Medical, our distributor, brings to IsoRay Medical a team of nine dedicated sales professionals strategically placed across Canada with exclusive rights to sell Cesium-131 brachytherapy seeds. Inter V Medical has been bringing new medical technologies, including brachytherapy and related products, to the Canadian market for nearly twenty years.”